Sorry, you need to enable JavaScript to visit this website.
For the short-term, non-continuous treatment of mild to moderate eczema (atopic dermatitis) not well controlled on topical therapies in people 12 and older without weakened immune systems or when those therapies are not recommended.

Results you can see and feel.

Results you can see and feel.

When it comes to your mild to moderate eczema, you deserve a treatment that works hard. OPZELURA has been shown to help people with mild to moderate eczema. OPZELURA was studied in two clinical trials, totaling more than 1200 people with mild to moderate eczema for 8 weeks, and was proven to help clear the visible signs of eczema and significantly reduce itch. Studies of OPZELURA included people with a range of skin tones ages 12 and older.

Individual results may vary.

In a Clinical Study
SKIN CLEARANCE
More than half of patients achieved
CLEAR OR ALMOST
CLEAR SKIN After
8 Weeks
54%
of those using
OPZELURA achieved
clear or almost
clear skin at Week 8 compared
with 15% of those not using
OPZELURA.
Similar results were seen in another clinical study.
 
Itch reduction
More than half of patients achieved
significant itch
reduction At
Week 8
52%
of those using
OPZELURA achieved
significant
itch reduction at week 8
compared to 15% not using
OPZELURA.
Similar results were seen in another clinical study.
In a Clinical Study
SKIN CLEARANCE
More than half of patients achieved
CLEAR OR ALMOST
CLEAR SKIN After
8 Weeks
54%
of those using
OPZELURA achieved
clear or almost
clear skin at Week 8 compared
with 15% of those not using
OPZELURA.
Similar results were seen in another clinical study.
Itch reduction
More than half of patients achieved
significant itch
reduction At
Week 8
52%
of those using
OPZELURA achieved
significant
itch reduction at week 8
compared to 15% not using
OPZELURA.
Similar results were seen in another clinical study.

OPZELURA was applied twice daily for 8 weeks and was applied by patients on areas of the skin where they had eczema, including sensitive ones such as the face. OPZELURA is only for use on affected areas that cover up to 20% of the body, as directed by your healthcare provider. OPZELURA is for use on the skin only. Do not use in your eyes, mouth or vagina. Stop using OPZELURA when signs and symptoms (e.g., itch, rash, and redness) of eczema resolve. Talk to your healthcare provider if you don't see an improvement within 8 weeks.

The following photos are from an actual patient who participated in the clinical study and show results from before the study and the results after 8 weeks of treatment with OPZELURA. Individual results may vary. OPZELURA was not studied in patients with severe eczema.

Image of a patient's skin after OPZELURA treatment
Image of a patient's skin before OPZELURA treatment

Individual results may vary.

OPZELURA was studied in 2 double-blind, vehicle-controlled clinical trials. This means that participants received either OPZELURA or just the vehicle—a cream with no active ingredients. Participants were not told which they received. More than 1200 people with mild to moderate eczema participated in these trials for 8 weeks, with 20% of participants ranging in age from 12-17 years old.

Who participated in the trials?

Gender

62% female, 38% male

Race/ethnicity
  • 70% Caucasian
  • 23% Black/African American
  • 4% Asian
Percentage of body area affected by eczema

3% to 20%. The average affected area was 9.8%

Severity*

Severity*: Participants had an eczema severity of 2 (mild) or 3 (moderate) on a scale of 0 to 4 (where 0 represented no eczema and 4 represented severe eczema)

*People with severe eczema were not included in the trial.

Were there any side effects?

The most common side effects of OPZELURA include: pain or swelling in your nose or throat (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), and runny nose (rhinorrhea). In clinical studies, these side effects were observed in at least 1% of people using OPZELURA.

Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.

My skin was a lot smoother.

- Clinical trial patient*
*Individual results may vary. OPZELURA is not for everyone.
 

OPZELURA
COPAY
SAVINGS CARD

Eligible* patients with commercial insurance
may pay as little as $10 per tube for OPZELURA.

*Terms & Conditions apply

 

Reach out
to your
Healthcare
Provider

Being open and honest with a doctor about your eczema can help them create a treatment plan that works for you.

IMPORTANT SAFETY INFORMATION AND INDICATION
Indication and Usage

OPZELURA is a prescription medicine
used on the skin (topical) for
short-term and non-continuous
treatment of mild to moderate
eczema (atopic dermatitis)
in non-immunocompromised people
12 and older whose disease is not
well controlled with topical
prescription therapies or when those
therapies are not recommended.

The use of OPZELURA along with
therapeutic biologics for atopic
dermatitis, other JAK inhibitors, or
strong immunosuppressants such
as azathioprine or cyclosporine is
not recommended.

Important Safety Information

OPZELURA cream is for use on the skin only. Do not use OPZELURA cream, in your eyes, mouth or vagina.

OPZELURA may cause serious side effects, including:

Serious Infections: OPZELURA cream contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.

OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.

Increased risk of death from all causes, including sudden cardiac death, has happened in people taking JAK inhibitors by mouth.

Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Some people have had lymphoma and other cancers while taking JAK inhibitors by mouth, especially if they are a current or past smoker. Some people have had skin cancers while taking OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA.

There is an increased risk of major cardiovascular events such as heart attack, stroke or cardiac death in people with cardiovascular risk factors and who are current or past smokers while using JAK inhibitors to treat inflammatory conditions.

Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening.

Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.

Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.

Before starting OPZELURA, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have an infection that keeps coming back
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have or had TB, or have been in close contact with someone with TB
  • have had shingles (herpes zoster) or hepatitis B or C
  • live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.
  • think you have an infection or have symptoms of an infection such as:
  • fever, sweating, or chills
  • muscle aches
  • cough or shortness of breath
  • blood in your phlegm
  • weight loss
  • warm, red, or painful skin or sores on your body
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than usual
  • feeling very tired
  • have ever had any type of cancer, or are a current or past smoker
  • have had blood clots in the veins of your legs or lungs in the past
  • have high cholesterol or triglycerides
  • have or have had low white or red blood cell counts
  • are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. There is a pregnancy exposure registry for individuals who use OPZELURA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463.
  • are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose.

After starting OPZELURA:

  • Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have.
  • Get emergency help right away if you have any symptoms of a heart attack or stroke while using OPZELURA, including:
  • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw, or stomach
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded
  • weakness in one part or on one side of your body
  • slurred speech
  • Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with OPZELURA, including: swelling, pain or tenderness in one or both legs, sudden, unexplained chest or upper back pain, or shortness of breath or difficulty breathing.
  • Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath or fever.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPZELURA include: pain or swelling in your nose or throat (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), and runny nose (rhinorrhea).

These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.

Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.